Obesity Clinical Trial
Official title:
Improving Body Composition, Strength, Function and Health Related Quality of Life in Older Individuals With Sarcopenic Obesity Through Lifestyle Modifications
Verified date | April 2016 |
Source | Queen Margaret University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United Kingdom: Research Ethics Committee |
Study type | Interventional |
This study evaluates the addition of a high-protein energy-restricted diet to exercise in the treatment of sarcopenic obesity in people aged 65 and over. Half of participants will follow a hypocaloric (500 kcal deficit) high-protein (1.2 -1.5 g Protein/ kg bodyweight) diet alongside an exercise regime, while the other half will follow the same exercise regime alongside their habitual diet . All participants will consume a Vitamin D3 tablet (25micrograms) 3 times a week to achieve a weekly intake of 75 micrograms. Total duration of the intervention will be 16 weeks.
Status | Active, not recruiting |
Enrollment | 18 |
Est. completion date | September 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 65 Years and older |
Eligibility |
Inclusion Criteria: - Independent living community-dwellers - Sarcopenic - Obese - Montreal Cognitive Assessment test (MoCA) score > or = 26 Exclusion Criteria: - Use of pacemaker - Lactose intolerance - Parkinson's disease - Unmanaged pain - Severe osteoporosis or arthritis - Use of corticosteroids - History of pulmonary embolus or myocardial infarction within the previous 2 years - Heart disease - Chronic obstructive pulmonary disease - Chronic kidney disease - Hypertension (resting systolic pressure >200mmHg, resting diastolic >100mmHg) - Acute systemic illnesses - Any other uncontrolled physical, psychological or mental condition that either prohibits adherence to the study protocol or increases significantly the health risks for the subject. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | Queen Margaret University | Musselburgh |
Lead Sponsor | Collaborator |
---|---|
Queen Margaret University | University of Birmingham |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Dietary intake | Assess changes in dietary intakes using 3-day recorded diet diaries from baseline to week 16 | Baseline, 16 weeks | No |
Other | Serum vitamin D (25-OH) levels | Assess changes in serum vitamin D levels at baseline and week 16 | Baseline, 16 weeks | No |
Primary | Skeletal muscle mass | Assess changes in total skeletal muscle mass (in kilograms) using bioelectrical impedance analysis at baseline, week 10 and week 16. | Baseline, 10 weeks, 16 weeks | No |
Primary | Body fat mass | Assess changes in body fat mass (in kg) using bioelectrical impedance analysis at baseline, week 10 and week 16. | Baseline, 10 weeks, 16 weeks | No |
Secondary | Physical Performance | Assess changes in Physical performance using the Short Physical Performance Battery test (SPPB) with a maximum score of 12. | Baseline, 10 weeks, 16 weeks | No |
Secondary | Dynamic Balance | Assess changes in dynamic balance using the 1-Arm Reach test (measured in cm). | Baseline, 10 weeks, 16 weeks | No |
Secondary | Functional Mobility | Assess changes in functional mobility using the timed (in seconds) Get Up-and-go test for 6 meters. | Baseline, 10 weeks, 16 weeks | No |
Secondary | Health related quality of life | Assess changes in health related quality of life using the Rand SF-36 questionnaire. | Baseline, 16 weeks | No |
Secondary | Central adiposity | Assess changes in central adiposity by measuring the Sagittal Abdominal Diameter (in cm) | Baseline, 10 weeks, 16 weeks | No |
Secondary | Handgrip strength | Assess changes in handgrip strength (in kg) using a handgrip dynamometer | Baseline, 10 weeks, 16 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |